Paul Wotton - Vericel Corp Director
| VCEL Stock | USD 46.42 1.04 2.29% |
Director
Dr. Paul Kevin Wotton is an Independent Director of the company. Dr. Wotton currently serves on the board of directors and was the founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a privatelyheld cell therapeutics company started in May 2016 and featured as one of the top ten emerging technologies of 2018 by Scientific American. Prior to that, he served as the President and Chief Executive Officer and a member of the board of directors of Ocata Therapeutics, Inc. from July 2014 until its acquisition by Astellas Pharma US, Inc. in February 2016 where he also served as the CoChairman of the Integration Management Office from February 2016 until May 2016. Prior to Ocata Therapeutics, Inc., Dr. Wotton served as President and Chief Executive Officer and a member of the board of directors of Antares Pharma, Inc. from October 2008 to June 2014. Prior to joining Antares, Dr. Wotton was the Chief Executive Officer of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is Chairman of the board of directors of Cynata Therapeutics Limited and a member of the board of directors of Veloxis Pharmaceuticals AS, where he is also Chairman of the compensation committee. Dr. Wotton also serves on the board of directors of Cadent Therapeutics and eXIthera Pharmaceuticals, both private companies. He is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, Dr. Wotton was named Ernst Young Entrepreneur of the Year for Life Sciences, New Jersey since 2017.
| Age | 57 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 64 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 588 5555 |
| Web | https://vcel.com |
Paul Wotton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Wotton against Vericel Corp stock is an integral part of due diligence when investing in Vericel Corp. Paul Wotton insider activity provides valuable insight into whether Vericel Corp is net buyers or sellers over its current business cycle. Note, Vericel Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vericel Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Wotton over three months ago Sale by Paul Wotton of 5000 shares of Vericel Corp | ||
Paul Wotton over six months ago Acquisition by Paul Wotton of 6500 shares of Vericel Corp subject to Rule 16b-3 | ||
Paul Wotton over six months ago Exercise or conversion by Paul Wotton of 2600 shares of Vericel Corp subject to Rule 16b-3 |
Vericel Corp Management Efficiency
The company has return on total asset (ROA) of (0.0129) % which means that it has lost $0.0129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0152) %, meaning that it created substantial loss on money invested by shareholders. Vericel Corp's management efficiency ratios could be used to measure how well Vericel Corp manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.0096. The value of Return On Capital Employed is expected to slide to -0.02. At this time, Vericel Corp's Intangible Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.28 this year, although the value of Non Currrent Assets Other will most likely fall to about 732.5 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Adi Goldin | Collplant Biotechnologies | 42 | |
| Paul Barbas | Dyne TherapeuticsInc | 59 | |
| Alexis Borisy | Blueprint Medicines Corp | 46 | |
| Edward Greissing | Chimerix | N/A | |
| Mason Freeman | Crinetics Pharmaceuticals | 66 | |
| Richard Kuersteiner | Dyne TherapeuticsInc | 76 | |
| Bruce Montgomery | Xencor Inc | 64 | |
| Shengyong Hu | Dyne TherapeuticsInc | 48 | |
| Timothy Wollaeger | Chimerix | 68 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| Peter Bains | Mereo BioPharma Group | 61 | |
| Alan Howarth | Terns Pharmaceuticals | 69 | |
| Fred Middleton | Chimerix | 67 | |
| Mark Goldberg | Blueprint Medicines Corp | 63 | |
| Daniel Tasse | Regenxbio | 58 | |
| Robert Baltera | Xencor Inc | 50 | |
| Catherine Gilliss | Chimerix | 66 | |
| Joseph Schepers | Chimerix | 58 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| Camille Samuels | Regenxbio | 44 | |
Management Performance
| Return On Equity | -0.0152 | ||||
| Return On Asset | -0.0129 |
Vericel Corp Ord Leadership Team
Elected by the shareholders, the Vericel Corp's board of directors comprises two types of representatives: Vericel Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vericel. The board's role is to monitor Vericel Corp's management team and ensure that shareholders' interests are well served. Vericel Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vericel Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Orlando, COO | ||
| Alan Rubino, Independent Director | ||
| Gerard Michel, CFO, Vice President - Corporate Development | ||
| Roland DeAngelis, Senior Operations | ||
| Robert Zerbe, Independent Chairman of the Board | ||
| Dominick Colangelo, President CEO, Chief Accounting Officer, Treasurer, Director | ||
| Ross Tubo, Chief Scientific Officer | ||
| Jonathan Hopper, Chief Medical Officer | ||
| Joseph Mara, CFO Treasurer | ||
| Patrick Helfrich, Vice Strategy | ||
| David Recker, Chief Medical Officer | ||
| Howard Leiner, Executive Vice President CTO | ||
| Mike Gilligan, Senior Sales | ||
| Patrick Fowler, Senior Strategy | ||
| Sean Flynn, Chief Officer | ||
| MB FRCSEd, Chief Officer | ||
| Heidi Hagen, Director | ||
| Heidi Hassen, Senior Resources | ||
| Steven Gilman, Director | ||
| Paul Wotton, Director | ||
| Dominick Esq, President CEO | ||
| Jonathan Siegal, VP Officer | ||
| Michael Halpin, Chief Officer | ||
| Eric Burns, Vice Relations | ||
| Kevin McLaughlin, Director |
Vericel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vericel Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0152 | ||||
| Return On Asset | -0.0129 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 2.17 B | ||||
| Shares Outstanding | 48.38 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 4.39 M | ||||
| Price To Earning | 357.33 X |
Vericel Corp Investors Sentiment
The influence of Vericel Corp's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Vericel. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Vericel Corp's public news can be used to forecast risks associated with an investment in Vericel. The trend in average sentiment can be used to explain how an investor holding Vericel can time the market purely based on public headlines and social activities around Vericel Corp Ord. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vericel Corp's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vericel Corp's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Vericel Corp's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Vericel Corp.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vericel Corp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vericel Corp's short interest history, or implied volatility extrapolated from Vericel Corp options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vericel Corp Ord is a strong investment it is important to analyze Vericel Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vericel Corp's future performance. For an informed investment choice regarding Vericel Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Vericel Corp Ord information on this page should be used as a complementary analysis to other Vericel Corp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Vericel Stock analysis
When running Vericel Corp's price analysis, check to measure Vericel Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vericel Corp is operating at the current time. Most of Vericel Corp's value examination focuses on studying past and present price action to predict the probability of Vericel Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vericel Corp's price. Additionally, you may evaluate how the addition of Vericel Corp to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Vericel Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.045 | Earnings Share (0.07) | Revenue Per Share 4.15 | Quarterly Revenue Growth 0.233 | Return On Assets (0.01) |
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.